Motexafin gadolinium: a novel radiosensitizer for brain tumors

References

• Wen PY, Black PM, Loeffler JS. Cancer: Principles and Practice of Oncology. DeVita VT Jr, Hellman SH, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA (2001).
   Google Scholar
• Cappuzzo F, Mazzoni F, Maestri A, Di Stefano A, Calandri C, Crino L. Medical treatment of brain metastases from solid tumours. Forum (Genova)10(2), 137–148 (2000).
   PubMedGoogle Scholar
• Greenberg H CW, Sandler HM. Brain Metastases. Greenberg H, Chandler WF, Sandler HM (Eds). Oxford University Press, NY, USA (1999).
   Google Scholar
• Ellis R, Gregor A. The treatment of brain metastases from lung cancer. Lung Cancer20(2), 81–84 (1998).
   Google Scholar
• Kelly K, Bunn PA Jr. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer20(2), 85–91 (1998).
   PubMed Web of Science ®Google Scholar
• Postmus PE, Haaxma-Reiche H, Smit EF et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy – a Phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol.18(19), 3400–3408 (2000).
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys.37(4), 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med.322(8), 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Hall E. Radiobiology for the Radiologist. Lippincott Williams & Wilkins, PA, USA (2000).
   Google Scholar
• Churchill-Davidson I. Hyperbaric oxygen and radiotherapy: general principles and problems. Nunt. Radiol.34(1), 5–13 (1968).
   PubMedGoogle Scholar
• Suh J, Stea B, Nabid A et al. Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral)in patients with brain metastases: results of the randomized REACH (RT-009) study. Proc. Am. Soc. Clin. Oncol.22(14S), 115S (2004).
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin. Radiat. Oncol.13(1), 13–21 (2003).
   PubMed Web of Science ®Google Scholar
• Carde P, Timmerman R, Mehta MP et al. Multicenter Phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J. Clin. Oncol.19(7), 2074–2083 (2001).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol.21(13), 2529–2536 (2003).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Shapiro WR, Glantz MJ et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J. Clin. Oncol.20(16), 3445–3453 (2002).
   PubMed Web of Science ®Google Scholar
• Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology212(3), 755–759 (1999).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Del Rowe J, Scott C, Werner-Wasik M et al. Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol.18(6), 1254–1259 (2000).
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst.85(9), 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Prados MD, Seiferheld W, Sandler HM et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys.58(4), 1147–1152 (2004).
   PubMed Web of Science ®Google Scholar
• Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89–05. Int. J. Radiat. Oncol. Biol. Phys.33(2), 339–348 (1995).
   PubMed Web of Science ®Google Scholar
• Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. A randomized Phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys.20(1), 53–58 (1991).
   PubMed Web of Science ®Google Scholar
• Shaw E, Scott C, Suh J et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol.21(12), 2364–2371 (2003).
   PubMed Web of Science ®Google Scholar
• Suh JH, Stea B, Nabid A et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol.24(1), 106–114 (2006).
   PubMed Web of Science ®Google Scholar
• Magda D, Lepp C, Gerasimchuk N et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol. Biol. Phys.51(4), 1025–1036 (2001).
   PubMed Web of Science ®Google Scholar
• Richards GM, Mehta MP. Motexafin gadolinium in the treatment of brain metastases. Expert Opin. Pharmacother.8(3), 351–359 (2007).
   PubMed Web of Science ®Google Scholar
• Mody TD, Fu L, Sessler JL. Texaphyrins: Synthesis and Development of a Novel Class of Therapeutic Agents. Karlin KD (Ed.), Wiley, NY, USA (2001).
   Google Scholar
• Sessler J. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallophyrins. J. Phys. Chem. A.103(7), 787–794 (1999).
   Google Scholar
• Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin. Cancer Biol.16(6), 466–476 (2006).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. Novel radiation sensitizers targeting tissue hypoxia. Oncology (Williston Park)13(10 Suppl. 5), 61–70 (1999).
   PubMedGoogle Scholar
• Rodrigus P. Motexafin gadolinium: a possible new radiosensitiser. Expert Opin. Investig. Drugs12(7), 1205–1210 (2003).
   PubMed Web of Science ®Google Scholar
• Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem.281(16), 10691–10697 (2006).
   PubMed Web of Science ®Google Scholar
• Donnelly ET, Liu Y, Fatunmbi YO, Lee I, Magda D, Rockwell S. Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int. J. Radiat. Oncol. Biol. Phys.58(5), 1570–1576 (2004).
   Google Scholar
• Lecane PS, Karaman MW, Sirisawad M et al. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res.65(24), 11676–11688 (2005).
   PubMed Web of Science ®Google Scholar
• Magda D, Lecane P, Miller RA et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res.65(9), 3837–3845 (2005).
   PubMed Web of Science ®Google Scholar
• Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys.45(4), 981–989 (1999).
   PubMed Web of Science ®Google Scholar
• Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol.59(7), 733–739 (2000).
   PubMed Web of Science ®Google Scholar
• Bohmer RM, Morstyn G. Uptake of hematoporphyrin derivative by normal and malignant cells: effect of serum, pH, temperature, and cell size. Cancer Res.45(11 Pt 1), 5328–5334 (1985).
   PubMedGoogle Scholar
• Ford JM, Endicott T, Alger JR, Earle J, Miles D, Phan S. A Phase I dose escalation trial of motexafin gadolinium as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.51(3S1), 205 (2001).
   Google Scholar
• Young SW, Sidhu MK, Qing F et al. Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. Invest. Radiol.29(3), 330–338 (1994).
   PubMed Web of Science ®Google Scholar
• Young SW, Qing F, Harriman A et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl Acad. Sci. USA93(13), 6610–6615 (1996).
   PubMed Web of Science ®Google Scholar
• Kesslering C. Selective uptake and retention of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) in tumors demonstrated by MRI in Phase I and Phase II clinical trials. Int. J. Radiat. Oncol. Biol. Phys.42, 263 (1998).
   PubMedGoogle Scholar
• Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized Phase III trial. J. Clin. Oncol.22(1), 157–165 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Gervais R, Chabot P et al. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a Phase III trial. Proc. Am. Soc. Clin. Oncol.24(18S) (2006) (Abstract 7014).
   Google Scholar
• Suh J, Mehta MP, Chang E et al. Phase II trial of motexafin gadolinium and cranial radiation in newly diagnosed glioblastoma multiforme (GBM). Int. J. Radiat. Oncol. Biol. Phys.54(2S), 246 (2002).
   Google Scholar
• Mehta M, Ford JM, Suh J, Phan S. Cumulative dose of motexafin gadolinium (MGD) and survival in newly diagnosed glioblastoma multiforme (GBM). Neuro-Oncology6(4), 378 (2004).
   Google Scholar
• Rosenthal DI, Becerra CR, Toto RD, Carbone DP, Frenkel EP. Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin. Am. J. Clin. Oncol.23(6), 593–598 (2000).
   Google Scholar
• Ford JM, Seiferheld W, Mehta M, Phan S, Curran W. Comparison of survival of patients in the Phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database. Proc. Am. Soc. Clin. Oncol.22, 106 (2003) (Abstract 425).
   Google Scholar
• De Stasio G, Rajesh D, Ford JM et al. Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei. Clin. Cancer Res.12(1), 206–213 (2006).
   Google Scholar